A quantitative approach for assessing significant improvements in elite sprint performance: Has IGF-1 entered the arena?

Drug Testing and Analysis

Volumn 5, Issue 6, 2013, Pages 384-389

  Ernst, Simon ^a   Simon, Perikles ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anabolic androgenic steroids; Doping; EPO; IGF 1; Time series analysis

Indexed keywords

HARMONIC ANALYSIS; INTERPOLATION; POLYNOMIAL APPROXIMATION; TIME SERIES ANALYSIS;

ANABOLIC ANDROGENIC STEROID; DOPING METHODS; DOPING SUBSTANCES; EFFECT SIZE; ERYTHROPOIETIN; INSULIN-LIKE GROWTH FACTOR-1; PERFORMANCE; PHYSICAL PERFORMANCE; QUANTITATIVE APPROACH; TIME-SERIES ANALYSIS;

SPORTS;

SOMATOMEDIN C;

ARTICLE; ATHLETE; DOPING; EFFECT SIZE; FEMALE; HUMAN; MALE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPORT; TIME SERIES ANALYSIS;

EID: 84879012270     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1406     Document Type: Article

References (30)

1. C.M. McHugh, R.T. Park, P.H. Sonksen, R.I. Holt Challenges in detecting the abuse of growth hormone in sport. Clin. Chem. 2005, 51, 1587.
2. WADA. The 2011 Prohibited List: International Standard. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf [December 23rd, 2011].
3. R.I. Holt, P.H. Sonksen Growth hormone, IGF-I and insulin and their abuse in sport. Brit. J. Pharmacol. 2008, 154, 542.
4. U. Meinhardt, A.E. Nelson, J.L. Hansen, V. Birzniece, D. Clifford, K.C. Leung, et al. The effects of growth hormone on body composition and physical performance in recreational athletes: A randomized trial. Ann. Intern. Med. 2010, 152, 568.
5. V. Birzniece, A.E. Nelson, K.K. Ho Growth hormone and physical performance. Trends Endocrin. Met. 2011, 22, 171.
6. N. Guha, A. Dashwood, N.J. Thomas, A.J. Skingle, P.H. Sonksen, R.I. Holt IGF-I abuse in sports. Curr. Drug Abuse Rev. 2009, 2, 263.
7. Spiegel Online. Der Dealer Olympias. Available at: http://www.spiegel.de/spiegel/0, 1518, 571031-3, 00.html [December 23rd, 2011].
8. A. Thomas, M. Kohler, W. Schanzer, P. Delahaut, M. Thevis Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst 2011, 136, 1003.
9. FDA. Priority NDA and BLA Approvals in 2005. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/PriorityNDAandBLAApprovals/ucm051208.htm [December 23rd, 2011].
10. M. Lames Leistungsentwicklung in der leichtathletik - ist doping als leistungsfördernder effekt identifizierbar? [Development of track and field performances - is there evidence for doping-effects?] dvs-Informationen 2002, 17, 15.
11. IAAF. Top Lists. Available at: http://www.iaaf.org/statistics/toplists/index.html [December 23rd, 2011].
12. IAAF. 12th IAAF World Championships In Athletics: IAAF Statistics Handbook, Berlin 2009, IAAF Media & Public Relations Department, Monte Carlo, 2009.
13. B.L. Welch The generalization of students problem when several different population variances are involved. Biometrika 1947, 34, 28.
14. J. Cohen Statistical Power Analysis for the Behavioral Sciences, 2nd Edn, Lawrence Erlbaum Associates, New Jersey, 1988.
15. J. Hartung, G. Knapp, B.K. Sinha Statistical Meta-Analysis with Application, John Wiley & Sons, Hoboken, New Jersey, 2008.
16. M. Cazzola A global strategy for prevention and detection of blood doping with erythropoietin and related drugs. Haematologica 2000, 85, 561.
17. W.W. Franke, B. Berendonk Hormonal doping and androgenization of athletes: A secret program of the German Democratic Republic government. Clin. Chem. 1997, 43, 1262.
18. WADA. A brief history of anti-doping. Available at: http://www.wada-ama.org/en/About-WADA/History/A-Brief-History-of-Anti-Doping/ [December 23rd, 2011].
19. U.S. Food and Drug Administration approves recombinant human erythropoietin for clinical use in the treatment of patients with anemia of chronic renal disease. Biotechnol. Law Rep. 1989, 8, 285.
20. F. Hoffmann-La Roche Ltd. Investor update. Available at http://www.roche.com/inv-update-2003-11-17 [December 23rd, 2011].
21. F. Lasne, L. Martin, J.A. Martin, J. de Ceaurriz Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control. Haematologica 2009, 94, 888.
22. F. Hoffmann-La Roche Ltd. Media Release. Available at: http://www.roche.com/med-cor-2008-07-24 [December 23rd, 2011].
23. S. Lamon, S. Giraud, L. Egli, J. Smolander, M. Jarsch, K.G. Stubenrauch, et al. A high-throughput test to detect C.E.R.A. doping in blood. J. Pharm. Biomed. Anal. 2009, 50, 954.
24. T.C. Malvey, T.D. Armsey 2nd. Tetrahydrogestrinone: The discovery of a designer steroid. Curr. Sports Med. Rep. 2005, 4, 227.
25. D.J. Handelsman Indirect androgen doping by oestrogen blockade in sports. Brit. J. Pharmacol. 2008, 154, 598.
26. P. Jozkow, M. Medras Growth hormone and IGF-1 as doping agents in competitive sport. Endokrynol. Pol. 2009, 60, 389.
27. B.P. Brennan, G. Kanayama, J.I. Hudson, H.G. Pope Jr. Human growth hormone abuse in male weightlifters. Am. J. Addict. 2011, 20, 9.
28. C.J. Mitchell, A.E. Nelson, M.J. Cowley, W. Kaplan, G. Stone, S.K. Sutton, et al. Detection of growth hormone doping by gene expression profiling of peripheral blood. J. Clin. Endocrinol. Metab. 2009, 94, 4703.
29. E.A. Chaler, C. Meazza, G. Guercio, M. Maceiras, M.A. Rivarola, K. Laarej, et al. Serum IGF-I and IGFBP-3 reference values from a chemiluminescent assay in normal children and adolescents of Hispanic and Italian origin: Presence of sexual dimorphism in IGF-I values. J. Pediatr. Endocr. Met. 2009, 22, 1127.
30. P.E. Sottas, N. Robinson, G. Fischetto, G. Dolle, J.M. Alonso, M. Saugy Prevalence of blood doping in samples collected from elite track and field athletes. Clin. Chem. 2011, 57, 762.